Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation

PURPOSE: Direct oral anticoagulant (DOAC) use for the prevention of thromboembolic complications in patients with non-valvular atrial fibrillation (AF) has increased steadily in Finland. DOACs have been shown to be cost-effective in comparison to warfarin, but published evidence of relative cost-eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Hallinen, Taru, Soini, Erkki, Asseburg, Christian, Linna, Miika, Eloranta, Pia, Sintonen, Sari, Kosunen, Mikko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370583/
https://www.ncbi.nlm.nih.gov/pubmed/34413661
http://dx.doi.org/10.2147/CEOR.S317078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370583/
https://www.ncbi.nlm.nih.gov/pubmed/34413661
http://dx.doi.org/10.2147/CEOR.S317078

Ejemplares similares